SG11202008687XA - Increasing tissue specific gene delivery by capsid modification - Google Patents

Increasing tissue specific gene delivery by capsid modification

Info

Publication number
SG11202008687XA
SG11202008687XA SG11202008687XA SG11202008687XA SG11202008687XA SG 11202008687X A SG11202008687X A SG 11202008687XA SG 11202008687X A SG11202008687X A SG 11202008687XA SG 11202008687X A SG11202008687X A SG 11202008687XA SG 11202008687X A SG11202008687X A SG 11202008687XA
Authority
SG
Singapore
Prior art keywords
gene delivery
specific gene
tissue specific
increasing tissue
capsid modification
Prior art date
Application number
SG11202008687XA
Other languages
English (en)
Inventor
Scott Allen Loiler
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of SG11202008687XA publication Critical patent/SG11202008687XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202008687XA 2018-03-16 2019-03-14 Increasing tissue specific gene delivery by capsid modification SG11202008687XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644317P 2018-03-16 2018-03-16
PCT/US2019/022353 WO2019178412A1 (fr) 2018-03-16 2019-03-14 Augmentation de l'administration de gènes spécifiques d'un tissu par modification de capside

Publications (1)

Publication Number Publication Date
SG11202008687XA true SG11202008687XA (en) 2020-10-29

Family

ID=67906893

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008687XA SG11202008687XA (en) 2018-03-16 2019-03-14 Increasing tissue specific gene delivery by capsid modification

Country Status (11)

Country Link
US (1) US20210087584A1 (fr)
EP (1) EP3765624A4 (fr)
JP (2) JP7304878B2 (fr)
KR (1) KR20200131843A (fr)
CN (1) CN111819286B (fr)
AU (1) AU2019234918A1 (fr)
BR (1) BR112020018354A2 (fr)
CA (1) CA3092353A1 (fr)
IL (1) IL277270A (fr)
SG (1) SG11202008687XA (fr)
WO (1) WO2019178412A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257628B2 (en) 2015-09-28 2023-04-01 Univ North Carolina Chapel Hill Methods and compositions for stealth virus antibody vectors
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
IL292297A (en) 2019-10-17 2022-06-01 Stridebio Inc Adeno-associated viral vectors for the treatment of Niemann-Pick type c disease
US20230365968A1 (en) 2022-04-06 2023-11-16 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
ES2411479T3 (es) * 2003-09-30 2013-07-05 The Trustees Of The University Of Pennsylvania Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos
US9409953B2 (en) * 2011-02-10 2016-08-09 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
EP2839014B1 (fr) * 2012-04-18 2020-12-16 The Children's Hospital of Philadelphia Composition et procédés pour un transfert génique hautement efficace à l'aide de variants de capside aav
IL297919A (en) 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Modified Aav and preparations, methods and uses for gene transfer to cells, organs and tissues
AU2015335923B2 (en) * 2014-10-21 2021-04-29 University Of Massachusetts Recombinant AAV variants and uses thereof
IL257628B2 (en) * 2015-09-28 2023-04-01 Univ North Carolina Chapel Hill Methods and compositions for stealth virus antibody vectors
MA45477A (fr) * 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
PT3445773T (pt) 2016-05-13 2023-03-13 4D Molecular Therapeutics Inc Cápsides variantes de vírus adeno-associado e métodos de utilização das mesmas
US20210299275A1 (en) * 2018-08-30 2021-09-30 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia

Also Published As

Publication number Publication date
EP3765624A4 (fr) 2022-05-25
US20210087584A1 (en) 2021-03-25
CN111819286B (zh) 2024-05-24
BR112020018354A2 (pt) 2020-12-29
IL277270A (en) 2020-10-29
KR20200131843A (ko) 2020-11-24
WO2019178412A1 (fr) 2019-09-19
JP2023115149A (ja) 2023-08-18
RU2020131998A (ru) 2022-04-18
JP2021515572A (ja) 2021-06-24
CA3092353A1 (fr) 2019-09-19
JP7304878B2 (ja) 2023-07-07
AU2019234918A1 (en) 2020-09-17
CN111819286A (zh) 2020-10-23
EP3765624A1 (fr) 2021-01-20

Similar Documents

Publication Publication Date Title
IL277270A (en) Augmenting tissue-specific gene delivery through capsid modification
CA195576S (en) Inhaler
IL286825A (en) Gene therapy for eye pathologies
CA187784S (en) Syringe
PT3612237T (pt) Terapia genética
IL279685A (en) Gene therapy
IL280165A (en) Glucocerebrosidase gene therapy
GB201910794D0 (en) Vaccine
CA207984S (en) Nasal cannula
GB202009824D0 (en) Inhaler
GB201707212D0 (en) Gene therapy for ciliopathies
GB201905301D0 (en) Gene therapy
GB201817470D0 (en) Gene therapy
GB201802326D0 (en) Gene therapy
GB201701968D0 (en) Gene therapy
EP3285813A4 (fr) Libération de gène smad7 en tant qu'agent thérapeutique
GB201906969D0 (en) Tissue splayer
GB201817469D0 (en) Gene therapy for retinal disease
GB2585141B (en) Syringe
GB201513151D0 (en) Functional gene replacement therapy
EP3760209C0 (fr) Thérapie génique spécifique du siège d'une lésion ischémique
GB201820982D0 (en) Gene Therapy
GB201811541D0 (en) Gene therapy
GB201910995D0 (en) DepthSet syringe
GB201908916D0 (en) Inhaler